Compare ALC & CCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALC | CCI |
|---|---|---|
| Founded | 1945 | 1994 |
| Country | Switzerland | United States |
| Employees | N/A | 4000 |
| Industry | Ophthalmic Goods | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9B | 37.8B |
| IPO Year | 2002 | 1998 |
| Metric | ALC | CCI |
|---|---|---|
| Price | $66.04 | $89.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | $89.38 | ★ $104.69 |
| AVG Volume (30 Days) | 2.1M | ★ 3.1M |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | 0.25% | ★ 4.95% |
| EPS Growth | N/A | ★ 111.25 |
| EPS | N/A | ★ 0.34 |
| Revenue | N/A | ★ $4,264,000,000.00 |
| Revenue This Year | $7.99 | N/A |
| Revenue Next Year | $6.38 | $1.72 |
| P/E Ratio | ★ $38.31 | $255.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $61.84 | $75.96 |
| 52 Week High | $92.55 | $115.76 |
| Indicator | ALC | CCI |
|---|---|---|
| Relative Strength Index (RSI) | 37.76 | 54.84 |
| Support Level | $61.84 | $87.44 |
| Resistance Level | $81.92 | $92.03 |
| Average True Range (ATR) | 1.66 | 2.28 |
| MACD | -0.45 | -0.19 |
| Stochastic Oscillator | 30.65 | 57.63 |
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 90% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown Castle has plans to divest its fiber business, which is expected to be finalized in the first half of 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.